MDGLMadrigal Pharmaceuticals, Inc.
Price
+7.3%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Nothing alarming, growing in the filings, the market undecided.
We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“MASH”), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH was previously known as nonalcoholic steatohepatitis (“NASH”). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation in the United States and the fastest-growing indication for liver transplantation in Europe.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Madrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $364M in Q2 2026 (quarter ended Jun 30, 2026), up 71% from the same quarter a year earlier. That came with net loss of $58M. For the full year FY2025, revenue was $958M (+432% year on year) and net income −$288M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the …Director or officer change · Form 8-K
- Jul 30, 2026Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- Jun 17, 20262026 Stock Plan On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting") of Madrigal Pharmaceuticals, Inc. (the "Company"), the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan (the "2026 Stock Plan"), which was previously adopted by the Company's Board of …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.